Date: 2016-03-16
Type of
information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Vaximm (Germany)
Product: VXM01
Action
mechanism:
- immunotherapy product/therapeutic vaccine. VXM01 is designed to stimulate the patients’ own immune system to destroy tumor-associated blood vessels, which are essential for tumors growth. VXM01 is given orally and acts in the gut to induce an anti-tumor response of the immune system.
Disease: metastatic colorectal cancer
Therapeutic
area: Cancer - Oncology
Country: Germany
Trial
details:
- This phase I study in patients with metastatic colorectal cancer with liver metastasis under second or third line therapy has been designed to examine safety, efficacy, and immune biomarkers after treatment with VXM01. (NCT02718430)
Latest
news:
Is
general: Yes
